Browse by People

Collapse authors list.
Munir, Talha, Cairns, David A, Bloor, Adrian, Allsup, David, Cwynarski, Kate, Pettitt, Andrew ORCID: 0000-0002-0907-8950, Paneesha, Shankara, Fox, Christopher P, Eyre, Toby A, Forconi, Francesco ORCID: 0000-0002-2211-1831 et al (show 23 more authors) , Elmusharaf, Nagah, Kennedy, Ben, Gribben, John, Pemberton, Nicholas, Sheehy, Oonagh, Preston, Gavin, Schuh, Anna, Walewska, Renata, Duley, Lelia ORCID: 0000-0001-6721-5178, Howard, Dena, Hockaday, Anna, Jackson, Sharon, Greatorex, Natasha, Girvan, Sean, Bell, Sue, Brown, Julia M, Webster, Nichola, Dalal, Surita, de Tute, Ruth, Rawstron, Andrew, Patten, Piers EM ORCID: 0000-0003-3320-3034, Hillmen, Peter and National Cancer Research Institute Chronic Lymphocytic Leukemia , (2024) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. The New England journal of medicine, 390 (4). pp. 326-337.

Collapse authors list.
Schuh, Anna H, Parry-Jones, Nilima, Appleby, Niamh, Bloor, Adrian, Dearden, Claire E, Fegan, Christopher, Follows, George, Fox, Christopher P, Iyengar, Sunil, Kennedy, Ben et al (show 7 more authors) , McCarthy, Helen, Parry, Helen M, Patten, Piers, Pettitt, Andrew R, Ringshausen, Ingo, Walewska, Renata and Hillmen, Peter (2018) Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. BRITISH JOURNAL OF HAEMATOLOGY, 182 (3). pp. 344-359.

Collapse authors list.
Pettitt, Andrew R, Jackson, Richard, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Polydoros, Fotis, Yap, Christina, Dodd, James, Bickerstaff, Matthew, Stackpoole, Michael, Khan, Umair T ORCID: 0000-0002-9470-3481, Carruthers, Stacey et al (show 16 more authors) , Oates, Melanie, Lin, Ke, Coupland, Sarah E ORCID: 0000-0002-1464-2069, Menon, Geetha, Kalakonda, Nagesh ORCID: 0000-0002-5300-1360, McCarthy, Helen, Bloor, Adrian, Schuh, Anna, Duncombe, Andrew, Dearden, Claire, Fegan, Christopher, Kennedy, Ben, Walewska, Renata, Marshall, Scott, Fox, Christopher P and Hillmen, Peter (2020) Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105 (12). pp. 2868-2871.